Navigation Links
Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/14/2010

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL).  A high objective response rate was maintained among patients treated with blinatumomab using an adapted schedule, comparable to that previously reported in patients receiving constant dosing.  Blinatumomab is the first in a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

The findings were presented on June 12, 2010 in an oral presentation (abstract # 0559) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Blinatumomab continues to demonstrate a long duration of response in heavily pre-treated non-Hodgkin's lymphoma patients," said Professor Ralph Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wuerzburg University Hospital, and the study's principal investigator. "Results of the expanded Phase 1 experience suggest that blinatumomab has the potential to alter the clinical course of disease in patients with a variety of NHL sub-types."

Phase 1 Study Design

This multi-center Phase 1 study evaluates the safety and tolerability of blinatumomab in adult patients with relapsed non-Hodgkin's lymphoma (NHL).  The key objectives of the study are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-lymphoma activity. &#
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
2. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
3. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
4. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
10. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s largest ... David Dreyer to the Board of Directors on ... and will also serve as chair of the Audit ... years of accounting, financial, compliance and operating experience in ... has served as chief financial officer, chief operating officer ...
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Alere Inc. ... rapid diagnostics, issued the following statement today in support ... Antibiotic-Resistant Bacteria. "As the global leader in ... for establishing a national strategy to address the serious ... to work with the Administration on initiatives to promote ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... Trial Showed REMICADE Therapy is More Likely to Induce ... ... Oct. 6 Data presented for the first time,from the Phase ... Therapy (SONIC) may provide new insights into,the approach to care of ...
... with ... in Clinical Trials -, PHOENIX, Oct. 6 ... focused on the treatment of,obesity and other central nervous ... (naltrexone SR /,bupropion SR), successfully achieved key objectives (lowered ...
Cached Medicine Technology:New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... 2014 Hastings and Hastings, a discount accident ... industry, announces a record number of visitors to its new ... of serious injury cases as well as auto accident cases ... related accident cases and others. Having served the state of ... the test of time when it comes to dedicated and ...
(Date:9/19/2014)... with The Melanoma Genetics Consortium, GenoMEL, an international research ... Journal of the National Cancer Institute that proves ... the first time, we have established that the genes ... in the risk of developing melanoma," said lead author ... at the University of Leeds (UK). , Telomeres ...
(Date:9/19/2014)... NJ (PRWEB) September 19, 2014 Visiting ... provider of home health care, hospice and palliative care ... to ring the Opening Bell yesterday at the New ... New Jersey philanthropist and social entrepreneur to care for ... Health Group has always worked to meet the urgent ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Melanoma risk found to have genetic determinant 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3
... MS, ... and sharing her story of hope and determination. , ... Bayfield, WI (PRWEB) April 7, 2010 -- Hopeful climbers have begun streaming in to ... highest peak. Last year,s successful climbers whose summit of Everest also completed their ...
... ... their newest Low level laser for body sculpting. Surprisingly Zerona has also been clinically ... addition to lowering the levels of Lipoprotein (LDL). , ... Houston, TX (PRWEB) April 6, 2010 -- A ...
... ... conversations about your brand, advertising campaign, competitors or product innovations. , ... (PRWEB) April 6, 2010 -- Six ... an easy, affordable way to gather insights needed to optimize marketing strategies, increase advertising ...
... for treatment, at higher rates than expected , TUESDAY, April ... visit hospitals repeatedly in search of treatment, according to new ... of sickle cell patients who visited the hospital returned within ... the ages of 18 and 30, were especially likely to ...
... An approach designed to reduce HIV/STDs previously used ... community-based organizations (CBOs), an important component in national strategies ... "at risk" youths can be reached. , A ... tested whether a proven HIV/STD risk-reduction intervention would work ...
... work better in protecting children from flu if they included ... Louis University research has found. "Adding a second influenza ... some of the guesswork out of strain selection and help ... M.D., lead investigator and director of the Center for Vaccine ...
Cached Medicine News:Health News:Woman with MS Summits Everest and Completes the Seven Summits 2Health News:Woman with MS Summits Everest and Completes the Seven Summits 3Health News:"Zerona" Lipo-Laser Penetrates Wellness Industry for Anti-aging, Weight Loss, Body Sculpting and Cardiac Health 2Health News:"Zerona" Lipo-Laser Penetrates Wellness Industry for Anti-aging, Weight Loss, Body Sculpting and Cardiac Health 3Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 3Health News:Roll-out of proven HIV/STD risk-reduction intervention with teens by community groups successful 2Health News:Building a better flu vaccine: Add second strain of influenza B 2
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... are offered as 1-piece or modular, in ... instruments may be customized with handles of ... insulation and flush ports. Many standard patterns ... may affect delivery times. , Please ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
Medicine Products: